JP6263533B2 - ジヒドロピリミジン化合物及び医薬におけるその適用 - Google Patents
ジヒドロピリミジン化合物及び医薬におけるその適用 Download PDFInfo
- Publication number
- JP6263533B2 JP6263533B2 JP2015527761A JP2015527761A JP6263533B2 JP 6263533 B2 JP6263533 B2 JP 6263533B2 JP 2015527761 A JP2015527761 A JP 2015527761A JP 2015527761 A JP2015527761 A JP 2015527761A JP 6263533 B2 JP6263533 B2 JP 6263533B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- methyl
- mmol
- ethyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCOC(C1=C(CN2C(CO)COCC2)NC(C2=SC=C*2)=NC1c(c(*)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C(CO)COCC2)NC(C2=SC=C*2)=NC1c(c(*)c1)ccc1F)=O 0.000 description 12
- GNGXTWQIBWAVCJ-YFKPBYRVSA-N CC1(C)OC[C@@H](C(O)=O)NC1 Chemical compound CC1(C)OC[C@@H](C(O)=O)NC1 GNGXTWQIBWAVCJ-YFKPBYRVSA-N 0.000 description 2
- MMGWUNSNHFHCSQ-RACUUBEBSA-N CC/C(/Br)=C(/C1N=C(C2SC=CN2)NC(CN2C(CO)COCC2)=C1C(OCC)=O)\C=C/CF Chemical compound CC/C(/Br)=C(/C1N=C(C2SC=CN2)NC(CN2C(CO)COCC2)=C1C(OCC)=O)\C=C/CF MMGWUNSNHFHCSQ-RACUUBEBSA-N 0.000 description 1
- IJNZVSTWTBTRBY-XTQSDGFTSA-N CCOC(/C(/C(c(c(Br)c1)ccc1F)N)=C(\CN1C(CC(O)O)COCC1)/NC(C)c(ncc(F)c1)c1F)=O Chemical compound CCOC(/C(/C(c(c(Br)c1)ccc1F)N)=C(\CN1C(CC(O)O)COCC1)/NC(C)c(ncc(F)c1)c1F)=O IJNZVSTWTBTRBY-XTQSDGFTSA-N 0.000 description 1
- FUYCYUFNABDHQB-UHFFFAOYSA-N CCOC(C1=C(CN(CC(C)(C)OC2)C2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CC(C)(C)OC2)C2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O FUYCYUFNABDHQB-UHFFFAOYSA-N 0.000 description 1
- CRACUJXIKOKMMX-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=N)NC(c2ncc(OC)[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=N)NC(c2ncc(OC)[s]2)=NC1c(c(Br)c1)ccc1F)=O CRACUJXIKOKMMX-UHFFFAOYSA-N 0.000 description 1
- XJYONJZVZMKDAC-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC([n]2ncnc2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC([n]2ncnc2)=NC1c(c(Br)c1)ccc1F)=O XJYONJZVZMKDAC-UHFFFAOYSA-N 0.000 description 1
- AGPBJJMUOKHVGI-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c(nc[s]2)c2Cl)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c(nc[s]2)c2Cl)=NC1c(c(Cl)c1)ccc1Cl)=O AGPBJJMUOKHVGI-UHFFFAOYSA-N 0.000 description 1
- JKUPDHLFBWRKPT-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2cnccn2)=NC1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2cnccn2)=NC1c(c(Cl)c1)ccc1F)=O JKUPDHLFBWRKPT-UHFFFAOYSA-N 0.000 description 1
- OSMSIFPGPYSKBH-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2n[n](C)cn2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2n[n](C)cn2)=NC1c(c(Br)c1)ccc1F)=O OSMSIFPGPYSKBH-UHFFFAOYSA-N 0.000 description 1
- VTAULEQFLVSKGF-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc(C(F)(F)F)[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc(C(F)(F)F)[s]2)=NC1c(c(Br)c1)ccc1F)=O VTAULEQFLVSKGF-UHFFFAOYSA-N 0.000 description 1
- CFKDUCCNYPBMDU-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc(F)[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc(F)[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O CFKDUCCNYPBMDU-UHFFFAOYSA-N 0.000 description 1
- SWFRMADRQUXBHT-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc[n]2C)=NC1c(c(C)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc[n]2C)=NC1c(c(C)c1)ccc1F)=O SWFRMADRQUXBHT-UHFFFAOYSA-N 0.000 description 1
- FMYUSYPZSFXDSC-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc[s]2)=NC1c1ccccc1Cl)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncc[s]2)=NC1c1ccccc1Cl)=O FMYUSYPZSFXDSC-UHFFFAOYSA-N 0.000 description 1
- CNBNQPQLFZDCRG-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncccc2Cl)=NC1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2ncccc2Cl)=NC1c(ccc(F)c1)c1Br)=O CNBNQPQLFZDCRG-UHFFFAOYSA-N 0.000 description 1
- LTOQXZDERBOSQF-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2nnc(C)[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2nnc(C)[s]2)=NC1c(c(Br)c1)ccc1F)=O LTOQXZDERBOSQF-UHFFFAOYSA-N 0.000 description 1
- WKAYRCYSFWNGBI-UHFFFAOYSA-N CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2nnc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)C2C(O)=O)NC(c2nnc[s]2)=NC1c(c(Br)c1)ccc1F)=O WKAYRCYSFWNGBI-UHFFFAOYSA-N 0.000 description 1
- UUPVEIPMBAVNBK-ATNAJCNCSA-N CCOC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O UUPVEIPMBAVNBK-ATNAJCNCSA-N 0.000 description 1
- KDTYLCPDNDPYEA-ATNAJCNCSA-N CCOC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1F)=O KDTYLCPDNDPYEA-ATNAJCNCSA-N 0.000 description 1
- XJLGNYJLRVXSBS-KZVXBFFYSA-N CCOC(C1=C(CN(CCO[C@@H]2C)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN(CCO[C@@H]2C)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O XJLGNYJLRVXSBS-KZVXBFFYSA-N 0.000 description 1
- MJOIGZSKABZNLZ-KZVXBFFYSA-N CCOC(C1=C(CN(CCO[C@@H]2C)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCO[C@@H]2C)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1F)=O MJOIGZSKABZNLZ-KZVXBFFYSA-N 0.000 description 1
- PPQHYGJIWIVWNU-IMMUGOHXSA-N CCOC(C1=C(CN(CC[O]=C2)[C@]2(C)C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CC[O]=C2)[C@]2(C)C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O PPQHYGJIWIVWNU-IMMUGOHXSA-N 0.000 description 1
- CUAAEOFQFPMMKH-ZVSMTPAHSA-N CCOC(C1=C(CN2C(COC([C@H](C(C)C)N)=O)COCC2)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2C(COC([C@H](C(C)C)N)=O)COCC2)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O CUAAEOFQFPMMKH-ZVSMTPAHSA-N 0.000 description 1
- ZVYNKLZYFVEQHS-UHFFFAOYSA-N CCOC(C1=C(CN2CC(C(O)=O)OCC2)NC(c2ncccn2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2CC(C(O)=O)OCC2)NC(c2ncccn2)=NC1c(c(Cl)c1)ccc1Cl)=O ZVYNKLZYFVEQHS-UHFFFAOYSA-N 0.000 description 1
- ILFIXUVIBJYIDE-UHFFFAOYSA-N CCOC(C1=C(CN2CC(CCC(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CCC(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O ILFIXUVIBJYIDE-UHFFFAOYSA-N 0.000 description 1
- TYFUQWNKMCKAGV-UHFFFAOYSA-N CCOC(C1=C(CN2CC(CCC(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2CC(CCC(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O TYFUQWNKMCKAGV-UHFFFAOYSA-N 0.000 description 1
- RLCZJMRIYCPKMC-UHFFFAOYSA-N CCOC(C1=C(CN2CC(CCC(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c([Br]=C)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CCC(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c([Br]=C)c1)ccc1F)=O RLCZJMRIYCPKMC-UHFFFAOYSA-N 0.000 description 1
- IKUVVJRIOYZARB-UHFFFAOYSA-N CCOC(C1=C(CN2CC(CCC(OC)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CCC(OC)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O IKUVVJRIOYZARB-UHFFFAOYSA-N 0.000 description 1
- YGHJKJFHCFNYBN-UHFFFAOYSA-N CCOC(C1=C(CN2CC(COC(C(C)(C)C)=O)OCC2)NC(c2n[nH]cn2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(COC(C(C)(C)C)=O)OCC2)NC(c2n[nH]cn2)=NC1c(c(Br)c1)ccc1F)=O YGHJKJFHCFNYBN-UHFFFAOYSA-N 0.000 description 1
- XBOYSNFVLIWDKG-KKFHFHRHSA-N CCOC(C1=C(CN2C[C@@H](C(C)(C)O)OCC2)NC(c2n[nH]cn2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@@H](C(C)(C)O)OCC2)NC(c2n[nH]cn2)=NC1c(c(Br)c1)ccc1F)=O XBOYSNFVLIWDKG-KKFHFHRHSA-N 0.000 description 1
- ADTXEYFGQRTICR-MJTSIZKDSA-N CCOC(C1=C(CN2C[C@H](CO)OCC2)NC(c2n[nH]cn2)=NC1c(c([Br]=C)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@H](CO)OCC2)NC(c2n[nH]cn2)=NC1c(c([Br]=C)c1)ccc1F)=O ADTXEYFGQRTICR-MJTSIZKDSA-N 0.000 description 1
- BMOHLXPVOPNMNL-UHFFFAOYSA-N COC(C1=C(CN(CCOC2)C2C(O)=O)NC(c([s]c2c3)nc2ccc3OC)=NC1c(c(Br)c1)ccc1F)=O Chemical compound COC(C1=C(CN(CCOC2)C2C(O)=O)NC(c([s]c2c3)nc2ccc3OC)=NC1c(c(Br)c1)ccc1F)=O BMOHLXPVOPNMNL-UHFFFAOYSA-N 0.000 description 1
- IJLHBRUCOZPNLF-MYJWUSKBSA-N COC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound COC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O IJLHBRUCOZPNLF-MYJWUSKBSA-N 0.000 description 1
- QWLJENRKYCPKHE-MYJWUSKBSA-N COC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound COC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O QWLJENRKYCPKHE-MYJWUSKBSA-N 0.000 description 1
- QJLRUAVQNXTCMO-MYJWUSKBSA-N COC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN(CCOC2)[C@@H]2C(O)=O)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1F)=O QJLRUAVQNXTCMO-MYJWUSKBSA-N 0.000 description 1
- POWWSIDMPMUMLG-UHFFFAOYSA-N COC(C1=C(CN2CC(C(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O Chemical compound COC(C1=C(CN2CC(C(O)=O)OCC2)NC(c2ncc[s]2)=NC1c(c(Br)c1)ccc1F)=O POWWSIDMPMUMLG-UHFFFAOYSA-N 0.000 description 1
- NACGKNUISYMTPT-FVRDMJKUSA-N COC(C1=C(CN2[C@@H](CO)COCC2)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O Chemical compound COC(C1=C(CN2[C@@H](CO)COCC2)NC(c2ncc[s]2)=NC1c(c(Cl)c1)ccc1Cl)=O NACGKNUISYMTPT-FVRDMJKUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210303033 | 2012-08-24 | ||
| CN201210303033.4 | 2012-08-24 | ||
| CN201310116949 | 2013-04-03 | ||
| CN201310116949.3 | 2013-04-03 | ||
| PCT/CN2013/001001 WO2014029193A1 (en) | 2012-08-24 | 2013-08-23 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526448A JP2015526448A (ja) | 2015-09-10 |
| JP2015526448A5 JP2015526448A5 (https=) | 2016-10-06 |
| JP6263533B2 true JP6263533B2 (ja) | 2018-01-17 |
Family
ID=50149385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527761A Active JP6263533B2 (ja) | 2012-08-24 | 2013-08-23 | ジヒドロピリミジン化合物及び医薬におけるその適用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9340538B2 (https=) |
| EP (1) | EP2888241B1 (https=) |
| JP (1) | JP6263533B2 (https=) |
| KR (1) | KR102148678B1 (https=) |
| CN (2) | CN103626752B (https=) |
| AU (1) | AU2013305390C1 (https=) |
| BR (1) | BR112015002858A2 (https=) |
| CA (1) | CA2876690C (https=) |
| DK (1) | DK2888241T3 (https=) |
| ES (1) | ES2640049T3 (https=) |
| HU (1) | HUE034919T2 (https=) |
| MX (1) | MX2015002511A (https=) |
| MY (1) | MY182403A (https=) |
| PL (1) | PL2888241T3 (https=) |
| PT (1) | PT2888241T (https=) |
| RU (1) | RU2655914C9 (https=) |
| SG (1) | SG11201408791TA (https=) |
| TW (1) | TWI668217B (https=) |
| WO (1) | WO2014029193A1 (https=) |
| ZA (1) | ZA201500451B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| MX2015002954A (es) * | 2012-09-10 | 2015-06-05 | Hoffmann La Roche | Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b. |
| CN103664899B (zh) * | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN104650069B (zh) * | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| RU2678990C1 (ru) * | 2013-11-19 | 2019-02-05 | Саншайн Лейк Фарма Ко., Лтд. | Соединения дигидропиримидина и их применение в фармацевтических препаратах |
| SG11201601813UA (en) * | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| JP6306750B2 (ja) | 2014-03-07 | 2018-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン |
| SG11201605896WA (en) * | 2014-03-28 | 2016-08-30 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and their application in pharmaceuticals |
| BR112016028000B1 (pt) * | 2014-05-30 | 2022-05-17 | Qilu Pharmaceutical Co., Ltd | Derivado de alça de di-hidropirimido como um inibidor de hbv |
| CN105153164B (zh) * | 2014-05-30 | 2018-10-30 | 齐鲁制药有限公司 | 作为hbv抑制剂的二氢嘧啶并环衍生物 |
| WO2016012470A1 (en) * | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
| US10098889B2 (en) | 2015-02-07 | 2018-10-16 | Sunshine Lake Pharma Co., Ltd. | Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals |
| CN107427514B (zh) * | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP6668468B2 (ja) * | 2015-11-03 | 2020-03-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| AR107633A1 (es) | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| WO2017198201A1 (en) * | 2016-05-19 | 2017-11-23 | Sunshine Lake Pharma Co., Ltd. | Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine |
| CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| CN109689059A (zh) * | 2016-08-24 | 2019-04-26 | 豪夫迈·罗氏有限公司 | Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法 |
| CN107793409B (zh) * | 2016-09-05 | 2022-09-27 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| WO2018045911A1 (zh) * | 2016-09-09 | 2018-03-15 | 浙江海正药业股份有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
| SG10202010180YA (en) * | 2016-11-18 | 2020-11-27 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Dihydropyrimidine compound and preparation method and use thereof |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| KR20200020887A (ko) * | 2017-06-27 | 2020-02-26 | 얀센 파마슈티카 엔.브이. | 헤테로아릴디히드로피리미딘 유도체 및 b형 간염 감염의 치료 방법 |
| CA3070004A1 (en) | 2017-07-27 | 2019-01-31 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| RU2020112854A (ru) | 2017-11-30 | 2021-12-30 | Арракис Терапьютикс, Инк. | Фотозонды, связывающие нуклеиновые кислоты, и способы их применения |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| EP3790866A4 (en) * | 2018-05-08 | 2022-03-02 | Janssen Sciences Ireland Unlimited Company | DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES |
| MA53023A (fr) * | 2018-06-26 | 2021-05-05 | Janssen Sciences Ireland Unlimited Co | Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| CN108947996B (zh) * | 2018-07-12 | 2022-01-18 | 山东大学 | 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| CN109232555B (zh) * | 2018-11-03 | 2020-06-02 | 深圳市第二人民医院 | 一种抗hbv的含氧杂环化合物 |
| CN109251201B (zh) * | 2018-11-03 | 2020-06-02 | 深圳市第二人民医院 | 一种抗hbv的含氮杂环化合物 |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| AU2020249331B2 (en) | 2019-03-25 | 2026-02-05 | F. Hoffmann-La Roche Ag | Solid forms of a compound of HBV core protein allosteric modifier |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CA3140690A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CN110204539B (zh) * | 2019-07-03 | 2021-07-23 | 山东大学 | 一种二氢嘧啶类前药及其制备方法和应用 |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| EP4003355A4 (en) * | 2019-07-31 | 2023-07-26 | Janssen Sciences Ireland Unlimited Company | DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| JP2023506528A (ja) * | 2019-12-20 | 2023-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染を治療する方法 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| WO2022052923A1 (zh) * | 2020-09-08 | 2022-03-17 | 和博医药有限公司 | 二氢嘧啶类化合物、其应用 |
| AR124719A1 (es) | 2021-01-29 | 2023-04-26 | Janssen Sciences Ireland Unlimited Co | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| EP4289842A4 (en) * | 2021-02-05 | 2025-01-08 | Hepagene Therapeutics (HK) Limited | Phenyldihydropyrimidine compound and use thereof |
| WO2022257942A1 (en) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
| CN116284080B (zh) * | 2023-02-23 | 2026-02-27 | 山东大学 | 一种含硼酸及硼酸频哪醇酯基团的二氢嘧啶类衍生物及其制备方法与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61271278A (ja) | 1985-05-20 | 1986-12-01 | イ− ア−ル スクイブ アンド サンズ インコ−ポレ−テツド | ２−置換チオまたはオキソ−４−アリ−ルまたはヘテロシクロ−５−カルボキシ−１，４−ジヒドロピリミジン |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| CA2154633A1 (en) * | 1995-01-25 | 1996-07-26 | Paul Harry Sandstrom | Silica reinforced rubber composition and use in tires |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| PE20110118A1 (es) * | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| WO2008024692A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | N-oxide aryl sulfones and sulfoxides |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328170B (zh) * | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| RU2443703C2 (ru) * | 2007-06-18 | 2012-02-27 | Саншайн Лейк Фарма Ко., Лтд | Бром-фенил замещенные тиазолилдигидропиримидины |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| WO2008154820A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| WO2010069147A1 (zh) * | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101575318B (zh) * | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| WO2013019967A1 (en) | 2011-08-02 | 2013-02-07 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| EA026977B1 (ru) | 2012-01-06 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| MX2015002954A (es) * | 2012-09-10 | 2015-06-05 | Hoffmann La Roche | Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b. |
-
2013
- 2013-08-23 CN CN201310373003.5A patent/CN103626752B/zh active Active
- 2013-08-23 KR KR1020147036508A patent/KR102148678B1/ko active Active
- 2013-08-23 JP JP2015527761A patent/JP6263533B2/ja active Active
- 2013-08-23 EP EP13830553.7A patent/EP2888241B1/en active Active
- 2013-08-23 HU HUE13830553A patent/HUE034919T2/en unknown
- 2013-08-23 RU RU2015110082A patent/RU2655914C9/ru active
- 2013-08-23 CA CA2876690A patent/CA2876690C/en active Active
- 2013-08-23 CN CN201510324031.7A patent/CN104926808B/zh active Active
- 2013-08-23 SG SG11201408791TA patent/SG11201408791TA/en unknown
- 2013-08-23 US US14/416,061 patent/US9340538B2/en active Active
- 2013-08-23 BR BR112015002858A patent/BR112015002858A2/pt active Search and Examination
- 2013-08-23 WO PCT/CN2013/001001 patent/WO2014029193A1/en not_active Ceased
- 2013-08-23 ES ES13830553.7T patent/ES2640049T3/es active Active
- 2013-08-23 DK DK13830553.7T patent/DK2888241T3/en active
- 2013-08-23 MX MX2015002511A patent/MX2015002511A/es unknown
- 2013-08-23 AU AU2013305390A patent/AU2013305390C1/en active Active
- 2013-08-23 PT PT138305537T patent/PT2888241T/pt unknown
- 2013-08-23 TW TW102130355A patent/TWI668217B/zh active
- 2013-08-23 PL PL13830553T patent/PL2888241T3/pl unknown
- 2013-08-23 MY MYPI2015700218A patent/MY182403A/en unknown
-
2015
- 2015-01-22 ZA ZA2015/00451A patent/ZA201500451B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6263533B2 (ja) | ジヒドロピリミジン化合物及び医薬におけるその適用 | |
| JP6524081B2 (ja) | ジヒドロピリミジン化合物及び医薬におけるその適用 | |
| KR102667040B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| RU2682672C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2022116244A (ja) | Ｐｄ－１／ｐｄ－ｌ１阻害剤 | |
| KR102665544B1 (ko) | 디하이드로피리미딘 화합물 및 약제에서의 이의 용도 | |
| CN103664925A (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| KR20210095143A (ko) | Hbv의 치료를 위한 5원 헤테로아릴 카르복스아미드 화합물 | |
| EP3512845A1 (en) | Hepatitis b core protein modulators | |
| JP2024537110A (ja) | Ｅｎｔ１阻害活性を有する大環状化合物 | |
| CA3099605A1 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170829 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6263533 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |